DRUGpreclinicalsmall molecule
gv-58
Brand names: GV-58
Mechanism
Selective Cav2 calcium-channel gating modifier. Stabilizes open state → enhances Ca2+ influx into motor nerve terminals → boosts ACh release. In severe SMA mice, GV-58 + DAP combination restored quantal content ~44% and improved muscle strength.
Approved indications
SMA preclinical (severe SMNΔ7 mouse)
Related claims (5)
| Type | Predicate | Conf | Source |
|---|---|---|---|
| motor function | Acute subcutaneous administration of GV-58 significantly increases behavioral measures of muscle strength in SMNΔ7 mice. | 53% | 36757138 |
| motor function | The combination of GV-58 and 3,4-DAP significantly increases behavioral measures of muscle strength when administered subcutaneously in SMNΔ7 mice. | 53% | 36757138 |
| drug target | GV-58 is a calcium channel gating modifier that acts as a drug target for SMA treatment. | 53% | 36757138 |
| drug efficacy | GV-58, a calcium channel gating modifier, restores neuromuscular transmission in SMNΔ7 mice when applied in vitro. | 45% | 36757138 |
| drug efficacy | The combination of GV-58 and 3,4-DAP (a potassium channel antagonist) significantly restores neuromuscular transmission in SMNΔ7 mice. | 45% | 36757138 |
Off-Target Findings (0)
No Boltz-2 / Chai-1 off-target panel claims recorded for this drug.